Inteliquent Inc (NASDAQ:IQNT) revealed that its 3Q2014 witnessed reduced expenses related to operations than the same one last year. The company also commented that it was witnessing encouraging business trends, especially on the market condition, expenses and revenue fronts. As such, the management is upbeat about the balance of the year and even the future.
Inteliquent Inc (NASDAQ:IQNT) said expenses relating to operations, sales and administration decreased 15% to $12.1 million. The company cited a drop in the expenses relating to professional fees as having a positive impact on the quarter. However, the company report $2.1 million in expenses that related to internal infestations by its Audit Committee.
Inteliquent Inc (NASDAQ:IQNT) revised its fiscal 2014 performance expectations and said it expected revenue in the range of $217-$220 million. Adjusted Ebitda is expected in the band of $77-$79 million.
Attunity Ltd (NASDAQ:ATTU)’s management said their newest product known as Attunity Maestro was generating a lot of interest, and they hope to tap into that opportunity for growth. Attunity Maestro is offered as a support for automated workflow management, and its enhanced version was recently launched. It is particularly aimed at managing of Big Data platforms. Since the launch of an expanded Attunity Maestro, Attunity Ltd (NASDAQ:ATTU) said they had received almost overwhelming feedback from existing users and prospects.
Enhancing its product portfolio and strengthening ties with partners are some of the fronts that Attunity Ltd (NASDAQ:ATTU) is looking into to boost its overall performance for the long-term.
Attunity Ltd (NASDAQ:ATTU) generated GAAP revenue of $9.4 million in the latest quarter. The figure was up 43% from the same period last year. The GAAP operating income for the quarter was $0.4 million.
Cempra Inc (NASDAQ:CEMP) said it was getting involved in several clinical trials for its antibiotic treatment known as solithromycin, which it licensed to Toyama Chemical of Japan. It said alongside its most recent quarter update that it had enrolled 860 subjects for a Phase 3 trial of the drug. The said trial will target patients with a form of pneumonia described as severe.
The company also updated that a Phase 3 study of solithromycin for gonorrhea had already started. Cempra Inc (NASDAQ:CEMP) also stated that the trial of the drug for bacterial infections in adolescents had been completed.
Cempra Inc (NASDAQ:CEMP) benefited a great deal in the latest quarter in connection with solithromycin. Its 3Q revenue increased to $7.8 million mainly supported by $4.3 million received in the form of milestone payments from the licensing of solithromycin.